Table 1 Characteristics of the HL cohort... | American Society of Hematology

Table 1

Characteristics of the HL cohort and survivors with subsequent malignancies

Characteristic			Subsequent malignancies in HL survivors*
	Entire cohort		Second		Third		Fourth
	No.	%	No.	%	No.	%	No.	%
Total	3122	100	832	100	126	100	16	100
Sex
Male	1776	56.9	410	49.3	42	33.3	4	25.0
Female	1346	43.1	422	50.7	84	66.7	12	75.0
Age at HL treatment, y
Median	27.3	—	29.2	—	26.9	—	20.1	—
<25	1288	41.3	293	35.2	52	41.3	10	62.4
25-34	1011	32.4	270	32.5	45	35.7	3	18.8
≥35	823	26.3	269	32.3	29	23.0	3	18.8
Treatment period HL
1965-1974	666	21.3	273	32.8	47	37.3	6	37.5
1975-1984	1043	33.4	329	39.5	61	48.4	9	56.3
1985-1995	1413	45.3	230	27.7	18	14.3	1	6.2
HL treatment†
RT only	941	30.1	307	36.9	68	54.0	7	43.8
CT only	319	10.2	41	4.9	2	1.6	0	0
RT + CT	1862	59.6	484	58.2	56	44.4	9	56.2
Follow-up after HL treatment, y
Median	22.6	—	24.6	—	30.5	—	32.1	—
5-9	308	9.9	66	7.9	2	1.6	1	6.2
10-19	869	27.8	210	25.3	16	12.7	1	6.2
20-29	1211	38.8	299	35.9	44	34.9	4	25.0
≥30	734	23.5	257	30.9	64	50.8	10	62.6

Characteristic			Subsequent malignancies in HL survivors*
	Entire cohort		Second		Third		Fourth
	No.	%	No.	%	No.	%	No.	%
Total	3122	100	832	100	126	100	16	100
Sex
Male	1776	56.9	410	49.3	42	33.3	4	25.0
Female	1346	43.1	422	50.7	84	66.7	12	75.0
Age at HL treatment, y
Median	27.3	—	29.2	—	26.9	—	20.1	—
<25	1288	41.3	293	35.2	52	41.3	10	62.4
25-34	1011	32.4	270	32.5	45	35.7	3	18.8
≥35	823	26.3	269	32.3	29	23.0	3	18.8
Treatment period HL
1965-1974	666	21.3	273	32.8	47	37.3	6	37.5
1975-1984	1043	33.4	329	39.5	61	48.4	9	56.3
1985-1995	1413	45.3	230	27.7	18	14.3	1	6.2
HL treatment†
RT only	941	30.1	307	36.9	68	54.0	7	43.8
CT only	319	10.2	41	4.9	2	1.6	0	0
RT + CT	1862	59.6	484	58.2	56	44.4	9	56.2
Follow-up after HL treatment, y
Median	22.6	—	24.6	—	30.5	—	32.1	—
5-9	308	9.9	66	7.9	2	1.6	1	6.2
10-19	869	27.8	210	25.3	16	12.7	1	6.2
20-29	1211	38.8	299	35.9	44	34.9	4	25.0
≥30	734	23.5	257	30.9	64	50.8	10	62.6

CT, chemotherapy; RT, radiotherapy; y, years.

Pathological confirmation was obtained for an estimated 95% of all second malignancies and 90% of all third malignancies.

Included primary and salvage therapy. RT includes all radiotherapy fields.